Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection (Q37933407)

25 August 2017

1 reference

title

Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection (English)

1 reference

25 August 2017

Clostridium difficile

0 references

antibiotic

0 references

author name string

Jennifer S Hardesty

series ordinal

1

1 reference

PubMed ID

21923589

25 August 2017

Paul Juang

series ordinal

2

1 reference

PubMed ID

21923589

25 August 2017

language of work or name

English

0 references

publication date

1 September 2011

1 reference

25 August 2017

1 reference

25 August 2017

31

1 reference

25 August 2017

877-886

1 reference

25 August 2017

9

1 reference

Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003

25 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Clinical practice. Antibiotic-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Meta-analysis to assess risk factors for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Risk factors for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Clinical risk factors for severe Clostridium difficile-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Treatment of Clostridium difficile-associated disease: old therapies and new strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

In vitro activity of OPT-80 against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

An epidemic, toxin gene-variant strain of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Fidaxomicin versus vancomycin for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Obesity increases the risks of diverticulitis and diverticular bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.877

21 January 2018

Identifiers

DOI

10.1592/PHCO.31.9.877

1 reference

25 August 2017

1 reference

PubMed ID

21923589